Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.

Add to Collection

2017 Feb Others S Kumar, HC Jang, NG Demirağ, TV Skjøth… - Diabetic …, 2017 - Wiley Online Library 98

Full Author : ['Kumar, S', 'Jang, H C', 'Demirag, N G', 'Skjoth, T V', 'Endahl, L', 'Bode, B']
Journal Title : Diabetic medicine : a journal of the British Diabetic Association
Chapter : Section3
Journal Year : 2017
Cited by : 48.0

AIMS: To investigate, in a 26-week, open-label, randomized, treat-to-target trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily vs insulin glargine (IGlar) once daily in adults with Type 2 diabetes, inadequately controll..... Read More

Keywords : ["oncedaily insulin degludecinsulin aspart compare", "oncedaily insulin glargine", "randomized treattotarget study", "type diabetes", "safety", "participant", "efficacy"]
PubMed Link : https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.13125
Google Scholar Link : https://scholar.google.com/scholar?cites=7903368968141204109&as_sdt=5,34&sciodt=0,34&hl=en&num=20

Have a Question?

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.